Submissions from 2024
A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors., Kathryn E Beckermann, Christine M Bestvina, Badi El Osta, Rachel E Sanborn, Hossein Borghaei, Philip Edward Lammers, Giovanni Selvaggi, Jennifer G Whisenant, Ellen Heimann-Nichols, Lynne Berry, Chih-Yuan Hsu, Yu Shyr, Leora Horn, and Heather Wakelee
Treatment practices and response in kaposiform hemangioendothelioma: A multicenter cohort study., Alexandra J Borst, Whitney Eng, Morgan Griffin, Kiersten W Ricci, Elissa Engel, Denise M Adams, Jillian Dayneka, Sally J Cohen-Cutler, Steven M Andreoli, Melinda D Wu, Allison P Wheeler, Kenneth M Heym, Shelley E Crary, Taizo A Nakano, Rachael R Schulte, Bhuvana A Setty, Thomas W McLean, Kristy S Pahl, Stefanos Intzes, Irina Pateva, Max Teitelbaum, Zili Zong, Yimei Li, and Michael R Jeng
Consensus Recommendations on the Management of Toxicity Associated with CD3xCD20 Bispecific Antibody Therapy., Jennifer L Crombie, Tara Graff, Lorenzo Falchi, Yasmin H Karimi, Rajat Bannerji, Loretta J Nastoupil, Catherine Thieblemont, Renata Ursu, Nancy L Bartlett, Victoria R Nachar, Jonathan Weiss, Jane Osterson, Krish Patel, Joshua D Brody, Jeremy S Abramson, Matthew A Lunning, Nirav N Shah, Ayed Ayed, Manali Kamdar, Benjamin M Parsons, Paolo Caimi, Ian W Flynn, Alex F Herrera, Jeff P Sharman, Marshall McKenna, Philippe Armand, Brad S Kahl, Sonali M Smith, Andrew D Zelenetz, Lihua E Budde, Martin Hutchings, Tycel J Phillips, and Michael Dickinson
Small-Volume Multifunctional Emergency Resuscitation Fluid Including Colloid Plasma Expander, Artificial Oxygen Carrier, and Coagulation Factors in Traumatic Hemorrhagic Shock When Blood Is Unavailable., Jonathan S Jahr, Hae Won Kim, Allen Rojhani, and Sandra Iskandar
Safety of Bioplasma FDP and Hemopure in rhesus macaques after 30% hemorrhage., Anthony E Pusateri, Clifford G Morgan, Leslie E Neidert, Michael M Tiller, Jacob Glaser, Richard B Weiskopf, Ismaeel Ebrahim, Willem Stassen, Sanjeev Rambharose, Scott H Mahoney, Lee A Wallis, Ewell M Hollis, Gerald T Delong, and Sylvain Cardin
Second Malignant Neoplasms Following Treatment for Hepatoblastoma: An International Report and Review of the Literature., Angela Trobaugh-Lotrario, Kenichiro Watanabe, Allison F O'Neill, Bozenna Dembowska-Bagińska, Beate Häberle, Andrew Murphy, Eiso Hiyama, Piotr Czauderna, Rebecka L Meyers, Max Langham, and James Feusner
Submissions from 2023
Identification and surveillance of rare relapse-initiating stem cells during complete remission post-transplantation., Marios Dimitriou, Teresa Mortera-Blanco, Magnus Tobiasson, Stefania Mazzi, Madeleine Lehander, Kari Högstrand, Mohsen Karimi, Gunilla Walldin, Monika Jansson, Sofie Vonlanthen, Per Ljungman, Saskia M C Langemeijer, Tetsuichi Yoshizato, Eva S Hellstrom-Lindberg, Petter S Woll, and Sten Eirik W Jacobsen
The transcriptomic landscape of normal and ineffective erythropoiesis at single-cell resolution., Raymond T Doty, Christopher G Lausted, Adam D Munday, Zhantao Yang, Xiaowei Yan, Changting Meng, Qiang Tian, and Janis L Abkowitz
Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies, B Garmezy, Brendan Curti, and See full list of authors in comments
Multicenter registry and test bed for extended outpatient hemodynamic monitoring: the hemodynamic frontiers in heart failure (HF, J Thomas Heywood, Kartik Munshi, Timothy Jordan, Evan Muse, Marat Fudim, Andrew J Sauer, Margaret McDermott, Hirak Shah, Arvind Bhimaraj, Rola Khedraki, Monique R Robinson, Patrick McCann, Elizabeth Volz, Ashrith Guha, Orvar Jonsson, Kunjan A Bhatt, Mosi K Bennett, Terrie Ann Benjamin, Maya Guglin, and Jacob Abraham
Preparing Hematology/Oncology Fellows for Success: Implementing an Annual Career Development and Research Retreat., Akeem R Lewis, Grace M Choong, Elizabeth Cathcart-Rake, Narjust Florez, Urshila Durani, Siddhartha Yadav, Harry Fuentes, Karl Sorensen, Daniel S Childs, Antoine Saliba, Jonas Paludo, and Timothy J Hobday
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for ultra-rare inherited bleeding disorders., Diane Nugent, Suchitra S Acharya, Kimberly J Baumann, Camille Bedrosian, Rebecca Bialas, Kai Brown, Deya Corzo, Amar Haidar, Catherine P M Hayward, Peter Marks, Marzia Menegatti, Margaret E Miller, Kate Nammacher, Roberta Palla, Skye Peltier, Rajiv K Pruthi, Michael Recht, Benny Sørensen, Michael Tarantino, Alisa S Wolberg, and Amy D Shapiro
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for ultra-rare inherited bleeding disorders., Diane Nugent, Suchitra S Acharya, Kimberly J Baumann, Camille Bedrosian, Rebecca Bialas, Kai Brown, Deya Corzo, Amar Haidar, Catherine P M Hayward, Peter Marks, Marzia Menegatti, Margaret E Miller, Kate Nammacher, Roberta Palla, Skye Peltier, Rajiv K Pruthi, Michael Recht, Benny Sørensen, Michael Tarantino, Alisa S Wolberg, and Amy D Shapiro
268 - Outpatient CAR T Cell Therapy Is Safe and Feasible in Patients with Lymphoma Treated in Non-University Medical Centers: A Multicenter, Retrospective Analysis, Krish Patel, Megumi Bailey, Neil Bailey, Suzanne Fanning, Kayla Gulley, Jens Frisvold, Sonia Glennie, Vanessa Dunleavy, Sandra Benitez-Kruidenier, Julia Parker, Shannon Williams, Suzan Sullivan, Carol Dean, Heidi Hohmann, Chiachun Lu, Catherine Tierney, Grace Mun, Daniel N Egan, and James Essell
Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy, Cristina Puig-Saus, Barbara Sennino, Songming Peng, Clifford L Wang, Zheng Pan, Benjamin Yuen, Bhamini Purandare, Duo An, Boi B Quach, Diana Nguyen, Huiming Xia, Sameeha Jilani, Kevin Shao, Claire McHugh, John Greer, Phillip Peabody, Saparya Nayak, Jonathan Hoover, Sara Said, Kyle Jacoby, Olivier Dalmas, Susan P Foy, Andrew Conroy, Michael C Yi, Christine Shieh, William Lu, Katharine Heeringa, Yan Ma, Shahab Chizari, Melissa J Pilling, Marc Ting, Ramya Tunuguntla, Salemiz Sandoval, Robert Moot, Theresa Hunter, Sidi Zhao, Justin D Saco, Ivan Perez-Garcilazo, Egmidio Medina, Agustin Vega-Crespo, Ignacio Baselga-Carretero, Gabriel Abril-Rodriguez, Grace Cherry, Deborah J Wong, Jasreet Hundal, Bartosz Chmielowski, Daniel E Speiser, Michael T Bethune, Xiaoyan R Bao, Alena Gros, Obi L Griffith, Malachi Griffith, James R Heath, Alex Franzusoff, Stefanie J Mandl, and Antoni Ribas
Advanced artificial intelligence-guided hemodynamic management within cardiac enhanced recovery after surgery pathways: A multi-institution review., V Seenu Reddy, David M Stout, Robert Fletcher, Andrew Barksdale, Manesh Parikshak, Chanice Johns, and Marc Gerdisch
A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B cell lymphoma., Geoffrey Shouse, Andy Kaempf, Max J Gordon, Andrew S Artz, David Yashar, Audrey M Sigmund, Gordon Smilnak, Steven M Bair, Agrima Mian, Lindsey A Fitzgerald, Amneet Bajwa, Samantha M Jaglowski, Neil Bailey, Mazyar Shadman, Krish Patel, Deborah M Stephens, Manali Kamdar, Brian T Hill, Jordan Gauthier, Reem Karmali, Loretta J Nastoupil, Adam S Kittai, and Alexey V Danilov
Outcomes of Patients Treated for Hepatoblastoma with Low Alpha-Fetoprotein and/or Small Cell Undifferentiated Histology: A Report from the Children's Hepatic Tumors International Collaboration (CHIC)., Angela D Trobaugh-Lotrario, Rudolf Maibach, Daniel C Aronson, Arun Rangaswami, Beate Häberle, Allison F O'Neill, Irene Schmid, Marc Ansari, Tomoro Hishiki, Sarangarajan Ranganathan, Rita Alaggio, Ronald R de Krijger, Yukichi Tanaka, Soo-Jin Cho, Christian Vokuhl, Rebecca Maxwell, Mark Krailo, Eiso Hiyama, Piotr Czauderna, Milton Finegold, James H Feusner, Marcio H Malogolowkin, Rebecka L Meyers, and Dolores Lopez-Terrada
Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Mantle Cell Lymphoma., Michael L Wang, Wojciech Jurczak, Pier Luigi Zinzani, Toby A Eyre, Chan Y Cheah, Chaitra S Ujjani, Youngil Koh, Koji Izutsu, James N Gerson, Ian Flinn, Benoit Tessoulin, Alvaro J Alencar, Shuo Ma, David Lewis, Ewa Lech-Maranda, Joanna Rhodes, Krish Patel, Kami Maddocks, Nicole Lamanna, Yucai Wang, Constantine S Tam, Talha Munir, Hirokazu Nagai, Francisco Hernandez-Ilizaliturri, Anita Kumar, Timothy S Fenske, John F Seymour, Andrew D Zelenetz, Binoj Nair, Donald E Tsai, Minna Balbas, Richard A Walgren, Paolo Abada, Chunxiao Wang, Junjie Zhao, Anthony R Mato, and Nirav N Shah
Submissions from 2022
A Simple Critical Care Provider Transfusion Education Program Reduces Blood Product Use, Ivan Martinez Avalos, Stephen Malkoski, and Mellody Descoteaux
307 - A Prospective Randomized Trial Comparing Conditioning with Either BEAM or High-Dose Melphalan Prior to Autologous Transplantation for Patients with Multiple Myeloma: An Evaluation of Interim Safety in Early Recovery Phase, Megumi Bailey, Tenzin Tsomo, Neil Bailey, Tori Braun, Chiachun Lu, Carol Dean, Shannon Williams, Gayle Funk, Joanna Fesler, Sonia Glennie, Judson Hall, Vanessa Dunleavy, Daniel N Egan, Raya Mawad, Livia Hegerova, Krish Patel, John M Pagel, and William Bensinger
Initial Efficacy and Safety of Acalabrutinib Plus RICE in Transplant Eligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Neil Bailey, Tori Braun, Megumi Bailey, Tenzin Tsomo, Jennie Szeto, Sandra Benitez Kruidenier, Vanessa Dunleavy, Joanna Fesler, Gayle Funk, Sonia Glennie, Judson Hall, Julia Parker, Daniel N Egan, Raya Mawad, Carol A. Dean, Suzan Sullivan, Chia Lu, Heidi Hohmann, Jordan Briggs, and Krish Patel
Autoimmune Hemolytic Anemia in Children: Laboratory Investigation, Disease Associations, and Treatment Strategies., Douglas Blackall and Lily Dolatshahi
Carfilzomib-Induced Thrombotic Microangiopathy: Focus on Pathogenesis., Odianosen Eigbire-Molen, Daniela Hermelin, and Douglas Blackall
Non-viral precision T cell receptor replacement for personalized cell therapy., Susan P Foy, Kyle Jacoby, Daniela A Bota, Theresa Hunter, Zheng Pan, Eric Stawiski, Yan Ma, William Lu, Songming Peng, Clifford L Wang, Benjamin Yuen, Olivier Dalmas, Katharine Heeringa, Barbara Sennino, Andy Conroy, Michael T Bethune, Ines Mende, William White, Monica Kukreja, Swetha Gunturu, Emily Humphrey, Adeel Hussaini, Duo An, Adam J Litterman, Boi Bryant Quach, Alphonsus H C Ng, Yue Lu, Chad Smith, Katie M Campbell, Daniel Anaya, Lindsey Skrdlant, Eva Yi-Hsuan Huang, Ventura Mendoza, Jyoti Mathur, Luke Dengler, Bhamini Purandare, Robert Moot, Michael C Yi, Roel Funke, Alison Sibley, Todd Stallings-Schmitt, David Y Oh, Bartosz Chmielowski, Mehrdad Abedi, Yuan Yuan, Jeffrey A Sosman, Sylvia M Lee, Adam J Schoenfeld, David Baltimore, James R Heath, Alex Franzusoff, Antoni Ribas, Arati V Rao, and Stefanie J Mandl
Verification of a Novel Minimally Invasive Device for the Isolation of Rare Circulating Tumor Cells (CTC) in Cancer Patients' Blood., Paul Friedrich Geus, Felix Hehnen, Sophia Krakowski, Klaus Lücke, Dave Hoon, Nikolaj Frost, Ulrich Kertzscher, and Gabi Wendt
Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study., Gareth P Gregory, Shaji Kumar, Ding Wang, Daruka Mahadevan, Patricia Walker, Nina Wagner-Johnston, Carolina Escobar, Rajat Bannerji, Divaya Bhutani, Julie Chang, Francisco J Hernandez-Ilizaliturri, Andreas Klein, John M Pagel, Witold Rybka, Andrew J Yee, Anne Mohrbacher, Mo Huang, Mohammed Farooqui, Patricia Marinello, and Hang Quach
Tyrosine kinase-altered spindle cell neoplasms with EGFR internal tandem duplications., Erica Kao, Navin Pinto, Angela Trobaugh-Lotrario, Gail H Deutsch, Yu Wu, Wenjing Wang, Erin R Rudzinski, and Yajuan J Liu
Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study., John D Powderly, Samuel J Klempner, Aung Naing, Johanna Bendell, Ignacio Garrido-Laguna, Daniel V T Catenacci, Matthew H Taylor, James J Lee, Fred Zheng, Feng Zhou, Xiaohua Gong, Hema Gowda, and Gregory L Beatty
Detecting blood transfusion reactions: What are vital signs anyway?, Jamie Roney, JoAnn D Long, Elizabeth R Cason, Lauren Johnston, Elaine Emery, Michella Deleon, Barbara E Whitley, and Karen Baggerly
The Utility of Fungal Blood Cultures: A Quality Improvement Study, Brigette Schuman, Elizabeth Savage, and Vanessa Hoytfox
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia., Jeff P Sharman, Miklos Egyed, Wojciech Jurczak, Alan Skarbnik, John M Pagel, Ian W Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Gillian Corbett, Laura Maria Fogliatto, Yair Herishanu, Versha Banerji, Steven Coutre, George Follows, Patricia Walker, Karin Karlsson, Paolo Ghia, Ann Janssens, Florence Cymbalista, Jennifer A Woyach, Emmanuelle Ferrant, William G Wierda, Veerendra Munugalavadla, Ting Yu, Min Hui Wang, and John C Byrd
Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)., Kohei Shitara, Toshihiko Doi, Hisashi Hosaka, Peter Thuss-Patience, Armando Santoro, Federico Longo, Ozgur Ozyilkan, Irfan Cicin, David J Park, Aziz Zaanan, Carles Pericay, Mustafa Özgüroğlu, Maria Alsina, Lukas Makris, Karim A Benhadji, and David H Ilson
Abstract A27: Impact of a validated composite comorbidity score on outcomes in patients treated with CAR T-cell therapy for diffuse large B cell lymphoma (DLBCL): A multicenter real-world evidence (RWE) study, Geoffrey Shouse, Neil Bailey, Krish Patel, and See all authors in comments
Impact of a Validated Composite Comorbidity Score on Outcomes in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Real-World Evidence (RWE) Study, Geoffrey Shouse, Neil Bailey, Krish Patel, and See all authors in comments
Association of PD-L1 expression, tumor mutational burden and immunotherapy with venous thrombosis in patients with solid organ malignancies., Rajat Thawani, Thomas Kartika, Benjamin Elstrott, Elizabeth Batiuk, Derrick L Tao, Sonia Gowda, Lilian Chen, Corinne Lavasseur, Nattapron Tun, Nicholas F Taflin, and Joseph Shatzel
Outcomes of Therapies and Resistance Mutations Following Non-Covalent Bruton's Tyrosine Kinase Inhibitor Treatment for Patients with Chronic Lymphocytic Leukemia and Richter Transformation, Meghan C. Thompson, Krish Patel, Neil Bailey, and See all authors in comments
Submissions from 2021
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration., Kenneth C Anderson, Daniel Auclair, Stacey J Adam, Amit Agarwal, Melissa Anderson, Herve Avet-Loiseau, Mark Bustoros, Jessica Chapman, Dana E Connors, Ajeeta Dash, Alessandra Di Bacco, Ling Du, Thierry Facon, Juan Flores-Montero, Francesca Gay, Irene M Ghobrial, Nicole J Gormley, Ira Gupta, Howard Higley, Jens Hillengass, Bindu Kanapuru, Dickran Kazandjian, Gary J Kelloff, Ilan R Kirsch, Brandon E Kremer, Ola Landgren, Elizabeth D Lightbody, Oliver C Lomas, Sagar Lonial, Maria Victoria Mateos, Rocio Montes de Oca, Lata Mukundan, Nikhil C Munshi, Elizabeth K O'Donnell, Alberto Orfao, Bruno Paiva, Reshma Patel, Trevor J Pugh, Karthik Ramasamy, Jill Ray, Mikhail Roshal, Jeremy A Ross, Caroline C Sigman, Katie L Thoren, Suzanne Trudel, Gary A Ulaner, Nancy Valente, Brendan M Weiss, Elena Zamagni, and Shaji K Kumar
Initial Safety Results from a Phase II Study of Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Neil Bailey, Tenzin Tsomo, Tori Braun, Jennie Szeto, William Bensinger, Daniel N Egan, Raya Mawad, Livia Hegerova, Gayle Funk, Joanna Fesler, Megumi Bailey, John M Pagel, and Krish Patel
Acalabrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia., John C Byrd, Jennifer A Woyach, Richard R Furman, Peter Martin, Susan O'Brien, Jennifer R Brown, Deborah M Stephens, Jacqueline Barrientos, Stephen Devereux, Peter Hillmen, John M Pagel, Ahmed Hamdy, Raquel Izumi, Priti Patel, Min Hui Wang, Nitin Jain, and William George Wierda
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies., Matthew S Davids, Owen A O'Connor, Wojciech Jurczak, Felipe Samaniego, Timothy S Fenske, Pier Luigi Zinzani, Manish R Patel, Nilanjan Ghosh, Bruce D Cheson, Enrico Derenzini, Danielle M Brander, James A Reeves, Wanda Knopinska-Posluszny, John N Allan, Tycel Phillips, Paolo F Caimi, Ewa Lech-Maranda, John M Burke, Richy Agajanian, Ruth Pettengell, Lori A Leslie, Chan Y Cheah, Gustavo Fonseca, James H Essell, Julio C Chavez, John M Pagel, Jeff P Sharman, Yanzhi Hsu, Hari P Miskin, Peter Sportelli, Michael S Weiss, and Ian W Flinn
Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia., Pinkal M Desai, Janice Brown, Saar Gill, Melham M Solh, Luke P Akard, Jack W Hsu, Celalettin Ustun, Charalambos Andreadis, Olga Frankfurt, James M Foran, John Lister, Gary J Schiller, Matthew J Wieduwilt, John M Pagel, Patrick J Stiff, Delong Liu, Irum Khan, Wendy Stock, Suman Kambhampati, Martin S Tallman, Lawrence Morris, John Edwards, Iskra Pusic, Hagop M Kantarjian, Richard Mamelok, Alicia Wong, Rodney Van Syoc, Lois Kellerman, Swapna Panuganti, Ramkumar Mandalam, Camille N Abboud, and Farhad Ravandi
Single-cell analysis of erythropoiesis in Rpl11 haploinsufficient mice reveals insight into the pathogenesis of Diamond Blackfan anemia., Raymond T Doty, Xiaowei Yan, Changting Meng, Christopher Lausted, Qiang Tian, and Janis L Abkowitz
Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia., Toby A Eyre, Nicole Lamanna, Lindsey E Roeker, Chaitra S Ujjani, Brian T Hill, Paul M Barr, Erick Lansigan, Bruce D Cheson, Maryam Yazdy, John N Allan, Joanna Rhodes, Stephen J Schuster, Chadi Nabhan, Alan Skarbnik, Lori Leslie, Prioty Islam, Katherine Whitaker, Catherine C Coombs, Hande H Tuncer, John M Pagel, Ryan Jacobs, Allison M Winter, Neil Bailey, Andrea Sitlinger, Anna H Schuh, George Follows, Christopher P Fox, Danielle M Brander, Mazyar Shadman, and Anthony R Mato
The chronic lymphocytic leukemia comorbidity index (CLL-CI): a three-factor comorbidity model., Max J Gordon, Andy Kaempf, Andrea Sitlinger, Geoffrey Shouse, Matthew Mei, Danielle M Brander, Tareq Salous, Brian T Hill, Hamood Alqahtani, Michael Choi, Michael C Churnetski, Jonathon B Cohen, Deborah M Stephens, Tanya Siddiqi, Xavier Rivera, Daniel Persky, Paul Wisnewski, Krish Patel, Mazyar Shadman, Byung Park, and Alexey V Danilov
Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, Brian T. Hill, Neil Bailey, Krish Patel, John M Pagel, and See full list of authors in comments
Awareness, Knowledge, and Preferences of United States (US) Patients with Chronic Lymphocytic Leukemia (CLL) and Their Caregivers Related to Finite Duration (FD) Therapy and Minimal (Measurable) Residual Disease (MRD), Brian Koffman, Neil Bailey, John M Pagel, and See all authors in comments
An empirical antigen selection method identifies neoantigens that either elicit broad anti-tumor T cell responses or drive tumor growth., Hubert Lam, Lisa K McNeil, Hanna Starobinets, Victoria L DeVault, Roger B Cohen, Przemyslaw Twardowski, Melissa L Johnson, Maura L Gillison, Mark N Stein, Ulka N Vaishampayan, Arthur P DeCillis, James J Foti, Vijetha Vemulapalli, Emily Tjon, Kyle Ferber, Daniel B DeOliveira, Wendy Broom, Parul Agnihotri, Elizabeth M Jaffee, Kwok-Kin Wong, Charles G Drake, Pamela M Carroll, Thomas A Davis, and Jessica Baker Flechtner
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study., Anthony R Mato, Nirav N Shah, Wojciech Jurczak, Chan Y Cheah, John M Pagel, Jennifer A Woyach, Bita Fakhri, Toby A Eyre, Nicole Lamanna, Manish R Patel, Alvaro Alencar, Ewa Lech-Maranda, William G Wierda, Catherine C Coombs, James N Gerson, Paolo Ghia, Steven Le Gouill, David John Lewis, Suchitra Sundaram, Jonathon B Cohen, Ian W Flinn, Constantine S Tam, Minal A Barve, Bryone Kuss, Justin Taylor, Omar Abdel-Wahab, Stephen J Schuster, M Lia Palomba, Katharine L Lewis, Lindsey E Roeker, Matthew S Davids, Xuan Ni Tan, Timothy S Fenske, Johan Wallin, Donald E Tsai, Nora C Ku, Edward Zhu, Jessica Chen, Ming Yin, Binoj Nair, Kevin Ebata, Narasimha Marella, Jennifer R Brown, and Michael Wang
How we approach hemangiomas in infants., Jennifer L R Mayer, Stefanos Intzes, Vikash S Oza, and Francine Blei
Current and future treatment strategies in chronic lymphocytic leukemia., Krish Patel and John M Pagel
Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study., Christiane Querfeld, John A Thompson, Matthew H Taylor, Jennifer A DeSimone, Jasmine M Zain, Andrei R Shustov, Carolyn Johns, Sue McCann, Gloria H Y Lin, Penka S Petrova, Robert A Uger, Naomi Molloy, Yaping Shou, and Oleg E Akilov
Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma., Paul G Richardson, Thierry Facon, William I Bensinger, Xavier Leleu, Frank Campana, Sandrine Macé, Marielle Chiron, Helgi van de Velde, and Joseph Mikhael
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results., Bijal D Shah, Michael R Bishop, Olalekan O Oluwole, Aaron C Logan, Maria R Baer, William B Donnellan, Kristen M O'Dwyer, Houston Holmes, Martha L Arellano, Armin Ghobadi, John M Pagel, Yi Lin, Ryan D Cassaday, Jae Park, Mehrdad Abedi, Januario Castro, Daniel J DeAngelo, Adriana K Malone, Raya Mawad, Gary Schiller, John Michael Rossi, Adrian Bot, Tong Shen, Lovely Goyal, Rajul K Jain, Remus Vezan, and William George Wierda
Impact of Comorbidities on Outcomes and Toxicity in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Rwe Study, Geoffrey Shouse, Neil Bailey, Krish Patel, and See all authors in comments
Outcomes of Chronic Lymphocytic Leukemia and Richter Transformation Following Discontinuation of Non-Covalent Bruton's Tyrosine Kinase Inhibitors, Meghan C. Thompson, Neil Bailey, and See full list of authors in comments
Addressing a New Challenge in Chronic Lymphocytic Leukemia: Outcomes of Therapies after Exposure to Both a Covalent Bruton's Tyrosine Kinase Inhibitor and Venetoclax, Meghan C. Thompson, John M Pagel, Neil Bailey, and See all authors in comments
Submissions from 2020
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study., Ghassan K Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, Gina Vaccaro, Davide Melisi, Raed Al-Rajabi, Andrew S Paulson, Mitesh J Borad, David Gallinson, Adrian G Murphy, Do-Youn Oh, Efrat Dotan, Daniel V Catenacci, Eric Van Cutsem, Tao Ji, Christine F Lihou, Huiling Zhen, Luis Féliz, and Arndt Vogel
A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma., Melissa Alsina, Ola Landgren, Noopur Raje, Ruben Niesvizky, William Bensinger, Jesus G Berdeja, Tibor Kovacsovics, David H Vesole, Belle Fang, Amy S Kimball, and David S Siegel
Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies., Stephen M Ansell, Ian Flinn, Matthew H Taylor, Branimir I Sikic, Joshua Brody, John Nemunaitis, Andrew Feldman, Thomas R Hawthorne, Tracey Rawls, Tibor Keler, and Michael J Yellin
Pembrolizumab in relapsed or refractory Richter syndrome., Philippe Armand, Niels Murawski, Daniel Molin, Jasmine Zain, Barbara Eichhorst, Zafer Gulbas, Eliza A Hawkes, John M Pagel, Tycel Phillips, Vincent Ribrag, Jakub Svoboda, Anastasios Stathis, Arkendu Chatterjee, Robert Orlowski, Patricia Marinello, and Beth Christian
Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in 3 Ongoing Clinical Studies in Relapsed/Refractory (R/R) Large B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Noneligible (TNE) Patients: Transcend NHL 001, Outreach, and PILOT, Carlos R. Bachier, M Lia Palomba, Jeremy S. Abramson, Charalambos Andreadis, Alison Sehgal, John E Godwin, Gerhard C. Hildebrandt, Tanya Siddiqi, Don Stevens, Thalia Farazi, Ana Kostic, Nikolaus S. Trede, Lei Wang, James Lymp, Tennille Thelen, Ken Ogasawara, and David G. Maloney
Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Neil Bailey, Tenzin Tsomo, Jennie Szeto, William Bensinger, Daniel N Egan, Livia Hegerova, Raya Mawad, Ami Batchelder, Joanna Fesler, Heather Holdread, Sonia Glennie, Judson Hall, Joseph Ferry, Megumi Bailey, David Kane, John M Pagel, and Krish Patel
The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia., Michael M Boyiadzis, Ivan Aksentijevich, Daniel A Arber, John Barrett, Renier J Brentjens, Jill Brufsky, Jorge Cortes, Marcos De Lima, Stephen J Forman, Ephraim J Fuchs, Linda J Fukas, Steven D Gore, Mark R Litzow, Jeffrey S Miller, John M Pagel, Edmund K Waller, and Martin S Tallman
Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children., Leonardo R Brandão, Manuela Albisetti, Jacqueline Halton, Lisa Bomgaars, Elizabeth Chalmers, Lesley G Mitchell, Ildar Nurmeev, Pavel Svirin, Tomas Kuhn, Ondrej Zapletal, Igor Tartakovsky, Monika Simetzberger, Fenglei Huang, Zhichao Sun, Jörg Kreuzer, Savion Gropper, Martina Brueckmann, Matteo Luciani, DIVERSITY Study Investigators, and Judy Felgenhauer (DIVERSITY Study Investigator)
A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphoma., Victor A Chow, Joseph G Rajendran, Darrell R Fisher, Frederick R Appelbaum, Ryan D Cassaday, Paul S Martin, Leona A Holmberg, Theodore A Gooley, Philip A Stevenson, John M Pagel, Damian J Green, Oliver W Press, and Ajay K Gopal
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study., Antonio Cuneo; Anthony R Mato; Gian Matteo Rigolin; Alfonso Piciocchi; Massimo Gentile; Luca Laurenti; John N Allan; John M Pagel; Danielle M Brander; Brian T Hill; Allison Winter; Nicole Lamanna; Constantine S Tam; Ryan Jacobs; Frederick Lansigan; Paul M Barr; Mazyar Shadman; Alan P Skarbnik; Jeffrey J Pu; Alison R Sehgal; Stephen J Schuster; Nirav N Shah; Chaitra S Ujjani; Lindsey Roeker; Ester Maria Orlandi; Atto Billio; Livio Trentin; Martin Spacek; Monia Marchetti; Alessandra Tedeschi; Fiorella Ilariucci; Gianluca Gaidano; Michael Doubek; Lucia Farina; Stefano Molica; Francesco Di Raimondo; Marta Coscia; Francesca Romana Mauro; Javier de la Serna; Angeles Medina Perez; Isacco Ferrarini; Giuseppe Cimino; Maurizio Cavallari; Rosalba Cucci; Marco Vignetti; Robin Foà; Paolo Ghia; and GIMEMA, European Research Initiative (ERIC) on CLL, US study group
The Efficacy of Passive Valve Antimicrobial Swab Caps Against Existing Clabsi Prevention Bundle in an Adult Hematology Inpatient Population: A Quality Improvement Initiative, Joseph F. Ferry, Neil Bailey, Vanessa Dunleavy, Joanna Fesler, Judson Hall, Sonia Glennie, William Bensinger, Raya Mawad, Krish Patel, Daniel N Egan, John M Pagel, and Livia Hegerova
The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma., Nathan H Fowler, Loretta Nastoupil, Sven De Vos, Mark Knapp, Ian W Flinn, Robert Chen, Ranjana H Advani, Sumeet Bhatia, Peter Martin, Raul Mena, Richard Eric Davis, Sattva S Neelapu, Karl Eckert, Jerry Ping, Melannie Co, Darrin M Beaupre, Jutta K Neuenburg, and M Lia Palomba
Disparities in the Occurrence of Late Effects following Treatment among Adolescent and Young Adult Melanoma Survivors., Alicia A Gingrich, Candice A M Sauder, Melanie Goldfarb, Qian Li, Ted Wun, and Theresa H M Keegan
Blood test shows high accuracy in detecting stage I non-small cell lung cancer., Cherylle Goebel, Christopher L Louden, Robert McKenna, Osita Onugha, Andrew Wachtel, and Thomas Long
The importance of age as prognostic factor for the outcome of patients with hepatoblastoma: Analysis from the Children's Hepatic tumors International Collaboration (CHIC) database., Beate Haeberle, Arun Rangaswami, Mark Krailo, Piotr Czauderna, Eiso Hiyama, Rudolf Maibach, Dolores Lopez-Terrada, Daniel C Aronson, Rita Alaggio, Marc Ansari, Marcio H Malogolowkin, Giorgio Perilongo, Allison F O'Neill, Angela Trobaugh-Lotrario, Kenichiro Watanabe, Irene Schmid, Dietrich von Schweinitz, Sarangarajan Ranganathan, Kenichi Yoshimura, Tomoro Hishiki, Yukichi Tanaka, Jin Piao, Yurong Feng, Eugenia Rinaldi, Davide Saraceno, Marisa Derosa, and Rebecka L Meyers
Allogeneic autophagosome-enriched composition for the treatment of disease, Traci Hilton, Sandra Aung, Rieneke van de Ven, Christopher Paustian, Tarsem Moudgil, Christopher Dubay, Christopher Twitty, Hong-Ming Hu, and Bernard A Fox
Maximizing Breast Cancer Therapy with Awareness of Potential Treatment-Related Blood Disorders., Henry G Kaplan, Gregory S Calip, and Judith A Malmgren
Management of CLL Patients Early in the COVID-19 Pandemic: An International Survey of CLL Experts, Brian Koffman, Anthony Mato, John C. Byrd, Alexey Danilov, Brad Hedrick, Chaitra Ujjani, Lindsey Roeker, Deborah M. Stephens, Matthew S. Davids, John M Pagel, and Mazyar Shadman
Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome., Je-Hwan Lee, Stefan Faderl, John M Pagel, Chul Won Jung, Sung-Soo Yoon, Animesh D Pardanani, Pamela S Becker, Howard Lee, Jeongeun Choi, Kyoungjune Lee, Minkyoung Kim, and Jorge E Cortes
Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry among Hematologic Malignancies., Manuela Cristina Matesan, Darrell R Fisher, Roger Wong, Ajay K Gopal, Damian J Green, William Bensinger, Brenda Sandmaier, John Pagel, Johnnie Orozco, Oliver W Press, Ryan Cassaday, Michele Wanner, Eric Hutchinson, Sujit Pal, Carolyn Thostenton, and Joseph Rajendran
Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry., Anthony R Mato, Jacqueline C Barrientos, Nilanjan Ghosh, John M Pagel, Danielle M Brander, Meghan Gutierrez, Karen Kadish, Brian Tomlinson, Reethi Iyengar, David Ipe, Sandhya Upasani, Carlos I Amaya-Chanaga, Murali Sundaram, Jennifer Han, Nick Giafis, and Jeff P Sharman
Phase 2 Study of the Safety and Efficacy of Umbralisib in Patients with CLL Who Are Intolerant to BTK or PI3Kδ Inhibitor Therapy., Anthony R Mato, Nilanjan Ghosh, Stephen J Schuster, Nicole Lamanna, John M Pagel, Ian W Flinn, Jacqueline Barrientos, Kanti R Rai, James A Reeves, Bruce D Cheson, Paul M Barr, Suman Kambhampati, Frederick Lansigan, Jeffrey J Pu, Alan P Skarbnik, Lindsey Elizabeth Roeker, Gustavo Fonseca, Andrea Sitlinger, Issam S Hamadeh, Colleen Dorsey, Nicole LaRatta, Hanna Weissbrot, Eline T Luning Prak, Patricia Y Tsao, Dana Paskalis, Peter Sportelli, Hari P Miskin, Michael S Weiss, Jakub Svoboda, and Danielle M Brander
Outcomes of COVID-19 in Patients with CLL: A Multicenter, International Experience., Anthony R Mato, Lindsey Elizabeth Roeker, Nicole Lamanna, John Allan, Lori Ann Leslie, John M Pagel, Krish Patel, Anders Osterborg, Daniel Wojenski, Manali Kamdar, Scott F Huntington, Matthew S Davids, Jennifer R Brown, Darko Antic, Ryan W Jacobs, Inhye E Ahn, Jeffrey J Pu, Krista Isaac, Paul M Barr, Chaitra Ujjani, Mark Blaine Geyer, Ellin Berman, Andrew D Zelenetz, Nikita Malakhov, Richard R Furman, Michael Koropsak, Neil Bailey, Lotta Hansson, Guilherme Fleury Perini, Shuo Ma, Christine E Ryan, Adrian Wiestner, Craig A Portell, Mazyar Shadman, Elise A Chong, Danielle M Brander, Suchitra Sundaram, Amanda N Seddon, Erlene Seymour, Meera Patel, Nicolas Martinez-Calle, Talha Munir, Renata Walewska, Angus Broom, Harriet Sarah Walter, Dima El-Sharkawi, Helen Parry, Matthew R Wilson, Piers E Patten, José-Ángel Hernández-Rivas, Fatima Miras, Noemi Fernández Escalada, Paola Ghione, Chadi Nabhan, Sonia Lebowitz, Erica B Bhavsar, Javier López-Jiménez, Daniel Naya, Jose Antonio Garcia-Marco, Sigrid S Skånland, Raul Cordoba, and Toby Andrew Eyre
Fertility Concerns and Access to Care for Stem Cell Transplant Candidates with Sickle Cell Disease., Adrienne D Mishkin, Markus Y Mapara, Michelle Barhaghi, and Ran Reshef
A Phase 2, Open-Label, Multicenter Study of Tazemetostat in Combination with Rituximab for the Treatment of Relapsed or Refractory Follicular Lymphoma, Krish Patel, Neil Bailey, and John M Pagel
Real World Observational Study Using Clonoseq® Next Generation Sequencing in Hematologic Malignancies: The 'Watch' Registry, Krish Patel, Neil Bailey, John M Pagel, and See all authors in comments
Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306)., Ruth Pettengell, Monika Długosz-Danecka, David Andorsky, David Belada, Pencho Georgiev, Donald Quick, Jack W Singer, Simran B Singh, Athanasios Pallis, Anton Egorov, and Gilles Salles
Worldwide Examination of Patients with CLL Hospitalized for COVID-19, Lindsey E. Roeker, Neil Bailey, and See full list of authors in comments
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial., Jeff P Sharman, Miklos Egyed, Wojciech Jurczak, Alan Skarbnik, John M Pagel, Ian W Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Gillian Corbett, Laura Maria Fogliatto, Yair Herishanu, Versha Banerji, Steven Coutre, George Follows, Patricia Walker, Karin Karlsson, Paolo Ghia, Ann Janssens, Florence Cymbalista, Jennifer A Woyach, Gilles Salles, William G Wierda, Raquel Izumi, Veerendra Munugalavadla, Priti Patel, Min Hui Wang, Sofia Wong, and John C Byrd
A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia., Catherine C Smith, Mark J Levis, Olga Frankfurt, John M Pagel, Gail J Roboz, Richard M Stone, Eunice S Wang, Paul L Severson, Brian L West, Mai H Le, Sabine Kayser, Bao Lam, Henry H Hsu, Chao Zhang, Gideon Bollag, and Alexander E Perl
Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration., Deborah M Stephens, Ken Boucher, Elizabeth Kander, Sameer A Parikh, Erin M Parry, Mazyar Shadman, John M Pagel, Jennifer Cooperrider, Joanna Rhodes, Anthony Mato, Allison Winter, Brian Hill, Sameh Gaballa, Alexey Danilov, Tycel Phillips, Danielle M Brander, Sonali M Smith, Matthew Davids, Kerry Rogers, Martha J Glenn, and John C Byrd
Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma., Sherilyn A Tuazon, Ryan D Cassaday, Theodore A Gooley, Brenda M Sandmaier, Leona A Holmberg, Stephen D Smith, David G Maloney, Brian G Till, Daniel B Martin, Victor A Chow, Joseph G Rajendran, Darrell R Fisher, Manuela C Matesan, Sally J Lundberg, Damian J Green, John M Pagel, Oliver W Press, and Ajay K Gopal
The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy., Chaitra Ujjani, Anthony Mato, Brian T Hill, John N Allan, Frederick Lansigan, Ryan Jacobs, Alan Skarbnik, Hande Tuncer, John M Pagel, Danielle Brander, Bruce Cheson, Paul Barr, Lindsey E Roeker, Jeffrey Pu, Nirav N Shah, Andre Goy, Stephen J Schuster, Nicole Lamanna, Alison Sehgal, Constantine S Tam, and Mazyar Shadman
Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia., Geoffrey L Uy, Ibrahim Aldoss, Matthew C Foster, Peter H Sayre, Matthew J Wieduwilt, Anjali S Advani, John E Godwin, Martha L Arellano, Kendra Sweet, Ashkan Emadi, Farhad Ravandi, Harry P Erba, Michael Byrne, Laura C Michaelis, Max S Topp, Norbert Vey, Fabio Ciceri, Matteo Giovanni Carrabba, Stefania Paolini, Gerwin Huls, Mojca Jongen-Lavrencic, Martin Wermke, Patrice Chevallier, Emmanuel Gyan, Christian Récher, Patrick Stiff, Kristen Pettit, Bob Löwenberg, Sarah Church, Erica Katherine Anderson, Jayakumar Vadakekolathu, Marianne T Santaguida, Michael P Rettig, John Muth, Teia Curtis, Erin Fehr, Kuo Guo, Jian Zhao, Ouiam Bakkacha, Kenneth Jacobs, Kathy Tran, Patrick Kaminker, Maya Kostova, Ezio Bonvini, Roland B Walter, Jan Kenneth Davidson-Moncada, Sergio Rutella, and John F DiPersio
Advances in targeted therapy for acute myeloid leukemia., Jifeng Yu, Peter Y Z Jiang, Hao Sun, Xia Zhang, Zhongxing Jiang, Yingmei Li, and Yongping Song
Submissions from 2019
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib., Farrukh T Awan, Anna Schuh, Jennifer R Brown, Richard R Furman, John M Pagel, Peter Hillmen, Deborah M Stephens, Jennifer Woyach, Elena Bibikova, Prista Charuworn, Melanie M Frigault, Ahmed Hamdy, Raquel Izumi, Bolan Linghu, Priti Patel, Min Hui Wang, and John C Byrd
Pituitary Apoplexy., Garni Barkhoudarian and Daniel F Kelly
Long-term follow-up of the RESONATE™ phase 3 trial of ibrutinib versus ofatumumab., John C Byrd, Peter Hillmen, Susan O'Brien, Jacqueline C Barrientos, Nishitha M Reddy, Steven Coutre, Constantine S Tam, Stephen P Mulligan, Ulrich Jaeger, Paul M Barr, Richard R Furman, Thomas J Kipps, Patrick Thornton, Carol Moreno, Marco Montillo, John M Pagel, Jan A Burger, Jennifer A Woyach, Sandra Dai, Remus Vezan, Danelle F James, and Jennifer R Brown
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results., John C Byrd, William George Wierda, Anna Schuh, Stephen Devereux, Jorge M Chaves, Jennifer R Brown, Peter Hillmen, Peter Martin, Farrukh T Awan, Deborah M Stephens, Paolo Ghia, Jacqueline Barrientos, John M Pagel, Jennifer A Woyach, Kathleen Burke, Todd Covey, Michael Gulrajani, Ahmed Hamdy, Raquel Izumi, Melanie M Frigault, Priti Patel, Wayne Rothbaum, Min Hui Wang, Susan O'Brien, and Richard R Furman
Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy., Victor A Chow, Ajay K Gopal, David G Maloney, Cameron J Turtle, Stephen D Smith, Chaitra S Ujjani, Mazyar Shadman, Ryan D Cassaday, Brian G Till, Yolanda D Tseng, Edus H Warren, Andrei R Shustov, Manoj P Menon, Sandra Bhark, Utkarsh H Acharya, Erin Mullane, Lindsay M Hannan, Jenna M Voutsinas, Ted A Gooley, and Ryan C Lynch
Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation., Jeffrey A Cohen, Laura E Baldassari, Harold L Atkins, J D Bowen, Christopher Bredeson, Paul A Carpenter, John R Corboy, Mark S Freedman, Linda M Griffith, Robert Lowsky, Navneet S Majhail, Paolo A Muraro, Richard A Nash, Marcelo C Pasquini, Stefanie Sarantopoulos, Bipin N Savani, Jan Storek, Keith M Sullivan, and George E Georges
The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia., Toby A Eyre, Lindsey E Roeker, Christopher P Fox, Satyen H Gohill, Renata Walewska, Harriet S Walter, Francesco Forconi, Angus Broom, Arvind Arumainathan, Danielle M Brander, John N Allan, Stephen J Schuster, Brian T Hill, Frederick Lansigan, Bruce D Cheson, Nicole Lamanna, Catherine C Coombs, Paul M Barr, Alan P Skarbnik, Mazyar Shadman, Chaitra S Ujjani, Laurie Pearson, John M Pagel, Ryan Jacobs, and Anthony R Mato
Reversal of acquired von Willebrand syndrome with allogeneic stem cell transplant for chronic lymphocytic leukemia., Livia Hegerova, Fiona He, Nicole D Zantek, Gregory M Vercellotti, Shernan G Holtan, and Mark T Reding
